Paratek Pharmaceuticals (NASDAQ:PRTK) Now Covered by StockNews.com

Investment analysts at StockNews.com started coverage on shares of Paratek Pharmaceuticals (NASDAQ:PRTK) in a research report issued to clients and investors on Sunday. The firm set a “hold” rating on the specialty pharmaceutical company’s stock.

Other research analysts also recently issued reports about the stock. HC Wainwright reissued a “neutral” rating and set a $2.15 price target on shares of Paratek Pharmaceuticals in a research note on Monday, August 7th. Jefferies Financial Group lowered shares of Paratek Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Wednesday, June 7th.

Paratek Pharmaceuticals Stock Performance

Shares of NASDAQ:PRTK opened at $2.22 on Friday. The stock has a market cap of $127.25 million, a PE ratio of -2.02 and a beta of 1.70. Paratek Pharmaceuticals has a 1-year low of $1.29 and a 1-year high of $3.65. The stock’s fifty day simple moving average is $2.20 and its two-hundred day simple moving average is $2.07.

Paratek Pharmaceuticals (NASDAQ:PRTK) last released its earnings results on Thursday, August 3rd. The specialty pharmaceutical company reported ($0.25) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.31) by $0.06. The firm had revenue of $39.99 million during the quarter, compared to analysts’ expectations of $34.63 million. On average, sell-side analysts forecast that Paratek Pharmaceuticals will post -0.79 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Paratek Pharmaceuticals news, CEO Evan Loh sold 48,967 shares of the firm’s stock in a transaction dated Wednesday, August 9th. The shares were sold at an average price of $2.20, for a total value of $107,727.40. Following the completion of the sale, the chief executive officer now owns 1,327,981 shares of the company’s stock, valued at $2,921,558.20. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. In other news, CEO Evan Loh sold 48,967 shares of the firm’s stock in a transaction dated Wednesday, August 9th. The shares were sold at an average price of $2.20, for a total value of $107,727.40. Following the sale, the chief executive officer now directly owns 1,327,981 shares in the company, valued at approximately $2,921,558.20. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, General Counsel William M. Haskel sold 34,526 shares of the stock in a transaction that occurred on Wednesday, August 9th. The shares were sold at an average price of $2.20, for a total transaction of $75,957.20. Following the completion of the transaction, the general counsel now directly owns 447,024 shares of the company’s stock, valued at $983,452.80. The disclosure for this sale can be found here. Insiders sold 142,346 shares of company stock valued at $313,161 in the last three months. Corporate insiders own 8.00% of the company’s stock.

Institutional Trading of Paratek Pharmaceuticals

Hedge funds have recently bought and sold shares of the business. Covestor Ltd purchased a new position in Paratek Pharmaceuticals in the second quarter valued at $25,000. UBS Group AG lifted its stake in shares of Paratek Pharmaceuticals by 7,455.9% in the 1st quarter. UBS Group AG now owns 10,276 shares of the specialty pharmaceutical company’s stock worth $26,000 after acquiring an additional 10,140 shares during the period. Cutter & CO Brokerage Inc. purchased a new position in shares of Paratek Pharmaceuticals during the 1st quarter worth approximately $28,000. CI Private Wealth LLC purchased a new position in shares of Paratek Pharmaceuticals in the 4th quarter valued at about $29,000. Finally, Commonwealth Equity Services LLC purchased a new position in Paratek Pharmaceuticals in the 4th quarter valued at approximately $31,000. Institutional investors and hedge funds own 53.60% of the company’s stock.

About Paratek Pharmaceuticals

Paratek Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of life-saving therapies for life-threatening diseases or other public health threats for civilian, government, and military use. Its products include NUZYRA, a once-daily oral and intravenous broad-spectrum antibiotic for the treatment of adult patients with community-acquired bacterial pneumonia, and acute skin and skin structure infections caused by susceptible pathogens; and SEYSARA, a once-daily oral therapy for the treatment of moderate to severe acne vulgaris.